Nkarta, Inc.
Clinical trials sponsored by Nkarta, Inc., explained in plain language.
-
Early trial tests 'Living Drug' for Tough-to-Treat kidney autoimmunity
Disease control Recruiting nowThis early-stage study is testing the safety and early effectiveness of a new cell therapy called NKX019 for people with active lupus nephritis or primary membranous nephropathy, two serious autoimmune kidney diseases. Participants will receive a one-time treatment cycle involvin…
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Early trial tests 'Living Drug' for tough autoimmune illnesses
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy called NKX019 in people with severe autoimmune diseases like systemic sclerosis, inflammatory muscle disease, and certain types of vasculitis. The main goals are to find a safe dose and see if the treatment is tolerable…
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC